Needham analyst Mayank Tandon downgrades Duck Creek Technologies (NASDAQ:DCT) from Buy to Hold.
Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay
Key Takeaways:
The company logged a revenue fall of 55% in the first half of the year and posted a loss of $131 million
Phase 3 clinical trials for its Covid-19 oral drug wrapped up in May but the company has still not yet filed an application to market the product
By Molly Wen
